SEZ6L Antibody [CoraFluor™ 1]
Novus Biologicals, part of Bio-Techne | Catalog # AF5598CL1
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
CoraFluor 1
Antibody Source
Polyclonal Goat IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Chinese hamster ovary cell line CHO-derived recombinant human SEZ6L
Leu29-Ala958
Accession # Q9BYH1
Leu29-Ala958
Accession # Q9BYH1
Specificity
Detects human SEZ6L in direct ELISAs and Western blots. In direct ELISAs, approximately 25% cross-reactivity with recombinant mouse (rm) BSRP-B is observed and less than 2% cross-reactivity with rmBSRP-A and rmBSRP-C is observed.
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Applications for SEZ6L Antibody [CoraFluor™ 1]
Application
Recommended Usage
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Formulation
PBS
Preservative
No Preservative
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark. Do not freeze.
Background: SEZ6L
Long Name
Seizure-related 6 Homolog-like
Alternate Names
Acig1, AIG1, Aig1L, BSRP-B, SEZ6L
Gene Symbol
SEZ6L
Additional SEZ6L Products
Product Documents for SEZ6L Antibody [CoraFluor™ 1]
Product Specific Notices for SEZ6L Antibody [CoraFluor™ 1]
CoraFluor (TM) is a trademark of Bio-Techne Corp. Sold for research purposes only under agreement from Massachusetts General Hospital. US patent 2022/0025254
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...